Alnylam Pharmaceuticals
ALNY
#570
Rank
A$54.68 B
Marketcap
$422.55
Share price
-1.75%
Change (1 day)
84.03%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -A$0.37 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are A$2.24 Billion. , an increase over its 2023 earnings that were of -A$0.51 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 -A$0.38 Billion-24.59%
2023 -A$0.51 Billion-67.84%
2022 -A$1.57 Billion36.93%
2021 -A$1.15 Billion-8.04%
2020 -A$1.25 Billion-15.66%
2019 -A$1.48 Billion12.23%
2018 -A$1.32 Billion62.91%
2017 -A$0.81 Billion17.78%
2016 -A$0.69 Billion43.44%
2015 -A$0.48 Billion60.69%
2014 -A$0.3 Billion98.2%
2013 -A$0.15 Billion
2011 -A$88.36 Million27.48%
2010 -A$69.31 Million-10.92%
2009 -A$77.81 Million95.77%
2008 -A$39.75 Million
2006 -A$63.67 Million-9.13%
2005 -A$70.07 Million34.74%
2004 -A$52.01 Million36.79%
2003 -A$38.02 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-A$0.97 Billion 154.87%๐Ÿ‡บ๐Ÿ‡ธ USA
A$7.70 B-2,129.54%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.42 B-210.72%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$16.71 Million-95.60%๐Ÿ‡บ๐Ÿ‡ธ USA
-A$74.47 Million-80.38%๐Ÿ‡บ๐Ÿ‡ธ USA
A$21.98 B-5,891.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
A$12.80 B-3,472.17%๐Ÿ‡ซ๐Ÿ‡ท France
-A$0.46 Billion 19.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel